Buy Rating Maintained on Lipocine Inc. (LPCN) as Target Climbs to $15

We recently published an article titled 10 Best Long Term Healthcare Stocks to Buy.

On January 21, H.C. Wainwright raised its price target on Lipocine Inc. (NASDAQ:LPCN) to $15 from $7 and maintained a Buy rating on the shares, citing the favorable safety profile observed for LPCN 1154. The firm sees the program as a potential value driver as it advances through late-stage development, particularly given the significant unmet need in postpartum depression and the potential for differentiation if safety and efficacy data remain strong.

On January 20, Lipocine Inc. (NASDAQ:LPCN) announced that enrollment and participant dosing have been completed in its Phase 3 clinical trial evaluating LPCN 1154 for the treatment of postpartum depression. The company expects to report topline safety and efficacy results early in the second quarter of 2026, according to CEO Mahesh Patel. Completion of enrollment marks an important milestone and reduces execution risk heading into a key clinical readout that could serve as a major catalyst for the stock if results are positive.

Lipocine Inc. (NASDAQ:LPCN) is a clinical-stage biopharmaceutical company focused on developing oral, lipid-based hormone therapies for men’s and women’s health. Founded in 1997 and headquartered in Salt Lake City, Utah, the company is advancing therapies targeting areas with meaningful unmet medical needs.

While we acknowledge the potential of LPCN as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than LPCN and that has a 100x upside potential, check out our report about the cheapest AI stock.

READ NEXT: 8 Up and Coming Streaming Companies and Services and 9 High Growth Canadian Stocks to Buy

Disclosure: None.